Osaka-Based Fuso Pharma Voluntary Recalls Heparin Products

Osaka-based Fuso Pharmaceutical announced May 2 it has started voluntarily recalling three kinds of heparin products in Japan, totaling 236,000 doses, due to a small amount of contaminant found in the products. According to the company, during a follow-up check after the products were distributed, the products were found to have the contaminant. The check found that the contaminant accounts for 0.2 percent, much less than 15-20 percent found in the U.S. cases. No adverse events related to Fuso's products were reported. A total of 1,237 Japanese dialysis facilities will be impacted by the recall. (Click here for more - Japanese language)